You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
《美股业绩》安进药厂业绩预测逊预期 市後股价偏软
阿思达克 02-03 09:30
道指成分股,美国安进药厂(Amgen)(AMGN.US)公布去年第四季业绩。季度收入66.34亿美元,按年升7%,符合市场预期。季度纯利16.15亿美元,按年跌5%。每股季度纯利2.76美元,经调整後为3.81美元,高於市场预期的3.4美元。季度派息每股1.6美元。

季内类风湿关节药Enbrel销售按年跌5%至12.7亿美元,低於市场预期的13亿美元。偏头痛药Aimovig销售1.04亿美元,低於市场预期的1.15亿美元。心血管药Repatha销售按年升27%至2.53亿美元,超出市场预期的2.23亿美元。

公司预期现财年经调整纯利介乎16至17美元,差於市场预期的17.03美元。全年销售预测介等乎258亿至266亿美元,中位数262亿美元,差於市场预期的264.5亿美元。

安进股价在延长交易时段跌1.7%,报236.5美元。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account